- RepliCel Life Sciences Inc. (RP) has received approval from the TSX Venture Exchange to extend the term for 1.81 million share purchase warrants
- The original term of the warrants was three years and expires on July 16th, 2023 but has now been extended to May 5th, 2025
- All the other terms of the warrants remain unchanged
- RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions
- RepliCel Life Sciences Inc. (RP) is unchanged, trading at $0.09 per share as of 3:48 p.m. ET
RepliCel Life Sciences (RP) has received approval from the TSX Venture Exchange to extend the term for 1.81 million share purchase warrants.
The original term of the warrants was three years and expires on July 16th, 2023 but has now been extended to May 5th, 2025. All the other terms of the warrants remain unchanged.
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the company believes is approximately one in three people in industrialized nations.
This includes aging, sun-damaged skin, pattern baldness, and chronic tendon degeneration. The cell therapy product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.
RepliCel Life Sciences Inc. (RP) is unchanged, trading at $0.09 per share as of 3:48 p.m. ET.
